Osamu Nagao

Learn More
BACKGROUND Thrombomodulin alfa (TM-α, recombinant thrombomodulin) significantly improved disseminated intravascular coagulation (DIC) when compared with heparin therapy in a phase III study. Post-marketing surveillance of TM-α was performed to evaluate the effects and safety in patients with sepsis-induced DIC. METHODS From May 2008 to April 2010, a total(More)
  • 1